IGF-1 DES vs IGF-1 LR3
How IGF-1 DES and IGF-1 LR3 compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
IGF-1 DES and IGF-1 LR3 come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
IGF-1 DES vs IGF-1 LR3, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | IGF-1 DES | IGF-1 LR3 |
|---|---|---|
| What it is | Naturally occurring 67-amino-acid N-terminally truncated form of insulin-like growth factor 1 | Synthetic 83-amino-acid analogue of insulin-like growth factor 1 (IGF-1) |
| Class / category | GH secretagogues | GH secretagogues |
| Evidence tier | Animal-only · Unclear · none in humans | Animal-only · Unclear · none in humans |
| Studied / approved for | IGF-binding-protein biology (laboratory research); Anabolic effects (animal research) | Muscle growth / anabolism (community use); Cell-culture / bioprocessing supplement (laboratory use) |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 0 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Nobody has established the safety of IGF-1 DES in humans. Animal studies show that poorly binding IGF-1 variants can lower blood glucose and increase organ weights, while the approved native IGF-1 drug carries serious hypoglycemia and neoplasia warnings. Those findings identify credible risks; they do not provide an adverse-event rate for IGF-1 DES. Research vials add identity, purity, dose, and sterility uncertainty. | No human safety data exists for IGF-1 LR3 — every risk here is read off IGF-1 biology and animal work, not measured in people using it to build muscle. Hypoglycemia is the most predictable: IGF-1 lowers blood sugar (it's the headline warning on mecasermin, the approved native-IGF-1 drug), which is why cautious users keep fast-acting carbs on hand. Animal data adds organ and tissue overgrowth — infused Long R3 IGF-1 enlarged guinea-pig organs — and IGF-1's pro-growth, anti-cell-death signaling raises a real, unsettled cancer-promotion concern. And because most of what's sold is reagent-grade cell-culture material rather than a pharmaceutical, a vial's true identity and dose ride on a seller who never had to prove either. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.Ballard et al., 1996 — des(1-3)IGF-I review (PubMed PMID 8930132)
- 2.Canalis et al., 1991 — des(1-3)IGF-I in rat bone-cell cultures (PubMed PMID 1647310)
- 3.Tomas et al., 1990 — des(1-3)IGF-I in lit/lit mice (PubMed PMID 2280209)
- 4.Tomas et al., 1997 — IGF-I variants in pigs and marmosets (PubMed PMID 9415072)
- 5.INCRELEX (mecasermin) prescribing information — DailyMed
- 6.ClinicalTrials.gov — IGF-1 DES registered-study search